Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Abstract

The prognosis of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) remains poor and current treatments are typically of limited benefit. Histone deacetylase (HDAC) inhibitors have proven effective for the treatment of relapsed/refractory PTCL. To date approved HDAC inhibitors for patients with T-cell lymphoma are vorinostat, romidepsin and, recently, belinostat. Here we review the pharmacology and the clinical activity of belinostat. Belinostat is a well-tolerated HDAC inhibitor that has shown activity in heavily pretreated patients with relapsed/refractory PTCL. Several clinical trials are currently investigating the use of belinostat in different cancers and in combination with other chemotherapeutic agents.

• Authors: Armin Rashidi, Amanda F Cashen
• Journal: Future oncology (London, England) (Future Oncol) Vol. 11 Issue 11 Pg. 1659-64 ( 2015) ISSN: 1744-8301 [Electronic] England
• PMID: 26043217 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Hydroxamic Acids
• Sulfonamides
• belinostat

Topics

• Antineoplastic Agents (chemistry, therapeutic use)
• Clinical Trials as Topic
• Humans
• Hydroxamic Acids (chemistry, therapeutic use)
• Lymphoma, T-Cell, Peripheral (drug therapy)
• Recurrence
• Retreatment
• Sulfonamides (chemistry, therapeutic use)